In vitro Drug Response and Molecular Markers Associated with Drug Resistance in Malignant Gliomas

@article{Fruehauf2006InVD,
  title={In vitro Drug Response and Molecular Markers Associated with Drug Resistance in Malignant Gliomas},
  author={John P Fruehauf and Henry Brem and Steven Brem and Andrew E. Sloan and Geoffrey R. Barger and Weidong Huang and Ricardo J. Parker},
  journal={Clinical Cancer Research},
  year={2006},
  volume={12},
  pages={4523 - 4532}
}
Purpose: Drug resistance in malignant gliomas contributes to poor clinical outcomes. We determined the in vitro drug response profiles for 478 biopsy specimens from patients with the following malignant glial histologies: astrocytoma (n = 71), anaplastic astrocytoma (n = 39), glioblastoma multiforme (n = 259), oligodendroglioma (n = 40), and glioma (n = 69). Experimental Design: Samples were tested for drug resistance to 1,3-bis(2-chloroethyl)-1-nitrosourea (BCNU), cisplatin, dacarbazine… 
View on AACR
clincancerres.aacrjournals.org
66 Citations
Highly Influential Citations
1
Background Citations
29
Results Citations
1

66 Citations

Citation Type

Citation Type

In Vitro Drug Response and Efflux Transporters Associated with Drug Resistance in Pediatric High Grade Glioma and Diffuse Intrinsic Pontine Glioma
TLDR
An in vitro drug screen on primary glioma cells, including three DIPG cultures, is performed to determine drug sensitivity of these tumours, to suggest that alternative ways of drug delivery may offer new possibilities for the treatment of pediatric high-gradeglioma patients, and DipG in particular.
p53 upregulated modulator of apoptosis sensitizes drug-resistant U251 glioblastoma stem cells to temozolomide through enhanced apoptosis
TLDR
It was found that adenoviruses expressing wild-type-PUMA not only lead to the apoptosis of CD133+ U251R cells alone, but also significantly increase their sensitivity toward TMZ by elevating the Bcl-2-associated X protein/B-cell lymphoma-2 ratio without alterations in MGMT expression, suggesting PUMA may be a suitable target for intervention to improve the therapeutic efficacy of TMZ.
Can in-vitro chemoresponse assays help find new treatment regimens for malignant gliomas?
TLDR
The results show reasonable agreement between two cell-based CSRAs that appear to confirm the clinical effectiveness of drugs used in GB treatment as long as pharmacological preconditions such as overcoming the blood–brain barrier are properly considered.
Pediatric glioblastoma cell line shows different patterns of expression of transmembrane ABC transporters after in vitro exposure to vinblastine
TLDR
The pediatric glioblastoma cell line SF188 shows different pattern of expression of multidrug resistance genes when exposed to vinblastine, and these preliminary findings may be useful in determining novel strategies of treatment for neuroepithelial pediatric brain tumors.
DNA repair and cancer stem-like cells--potential partners in glioma drug resistance?
Role of multidrug resistance in glioblastoma chemoresistance: Focus on ABC transporters
Proteomic Analysis of Glioma Chemoresistance
  • K. Suk
  • Biology
    Current neuropharmacology
  • 2012
TLDR
Among numerous proteins that were up- or down-regulated in drug-resistant glioma cells, lipocalin 2 and integrin β3 (ITGB3) were identified as key proteins that determine the survival and death of gliomas cells, and LCN2, ITGB3, and other proteins identified by proteomic analysis could be utilized to overcomeglioma chemoresistance.
Current Trends in Targeted Therapies for Glioblastoma Multiforme
TLDR
Up-to-date clinical trials of GBM treatments are reviewed to aim at more therapeutical effect than conventional therapies that are ongoing or are about to launch in clinical settings and discuss future perspectives.
A Nanoparticle Carrying the p53 Gene Targets Tumors Including Cancer Stem Cells, Sensitizes Glioblastoma to Chemotherapy and Improves Survival
TLDR
It is demonstrated that scL crosses the BBB and efficiently targets GBM, as well as cancer stem cells, which have been implicated in recurrence and treatment resistance in many human cancers, and scL-p53 sensitized both CSCs and bulk tumor cells to TMZ, increasing apoptosis.
Heterogeneity of Human Gliomas: Glutathione-S-Transferase Expression Profile During Disease Progression and Under Systemic Therapy
TLDR
No significant differences in gene and protein expression were detected between the different types of gliomas, suggesting that glioma chemoresistance is probably multifactorial and GSTP1-independent.
...
1
2
3
4
5
...

References

SHOWING 1-10 OF 139 REFERENCES
Differential expression of drug resistance genes and chemosensitivity in glial cell lineages correlate with differential response of oligodendrogliomas and astrocytomas to chemotherapy.
TLDR
Support is provided for the hypothesis that properties of glial cells retained in gliomas may contribute to the differential chemosensitivity of glia neoplasms.
Anticancer drug resistance in primary human brain tumors
  • M. Bredel
  • Biology, Medicine
    Brain Research Reviews
  • 2001
A Prospective Blinded Study of the Predictive Value of an Extreme Drug Resistance Assay in Patients Receiving CPT-11 for Recurrent Glioma
TLDR
Predictive reliability of an extreme drug resistance (EDR) to identify clinical resistance to irinotecan (CPT-11) is evaluated, and the notion that patients should avoid agents to which their tumor demonstrates EDR is supported.
Levels of multidrug resistance (MDR1) P-glycoprotein expression by human breast cancer correlate with in vitro resistance to taxol and doxorubicin.
TLDR
The data suggest that Pgp contributes to clinical MDR1-related drug resistance, and both intrinsic and acquired expression of Pgp in breast cancer may contribute in part to therapeutic failure and relapse.
Breast Cancer Survival and in Vitro Tumor Response in the Extreme Drug Resistance Assay
TLDR
In this cohort of breast cancer patients treated with chemotherapy, summed EDR scores were significantly associated with time to tumor progression and overall survival, and EDR results may offer a method for optimizing treatment selection.
Correlation of tumor O6 methylguanine-DNA methyltransferase levels with survival of malignant astrocytoma patients treated with bis-chloroethylnitrosourea: a Southwest Oncology Group study.
  • K. Jaeckle, H. Eyre, +7 authors S. Schold
  • Medicine
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • 1998
TLDR
The MGMT level in tumor tissue specimens may be a predictive marker of survival in patients with malignant astrocytoma that is independent of other known prognostic factors (age, performance status, histology).
IN-VITRO CLONOGENIC ASSAY FOR PREDICTING RESPONSE OF OVARIAN CANCER TO CHEMOTHERAPY
Association between in vitro platinum resistance in the EDR assay and clinical outcomes for ovarian cancer patients.
TLDR
Patients with tumors demonstrating in vitro EDR to platinum were at significantly increased risk for progression and death when treated with standard platinum-based regimens, and may benefit from entry onto trials with novel agents or combinations.
Multidrug resistance gene (MDR 1) expression in neuro-axial tumours of children and young adults.
TLDR
MDR1 may play a role in the chemoresistance of neuro-axial tumours either by its expression in the normal blood-brain barrier or by forming a blood-tumour barrier, and the proportion of vessels expressing Pgp may determine the degree of resistance.
Single-agent chemotherapy of brain tumors. A five-year review.
TLDR
Identification of effective single chemotherapeutic agents for brain tumors must precede the rational use of multiple drug combinations and Administration of glucocorticoids was not found to bias the frequency of response.
...
1
2
3
4
5
...